Advances and challenges in therapeutic targeting of NRF2

Albena T. Dinkova-Kostova (Lead / Corresponding author), Ian M. Copple (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

48 Citations (Scopus)
117 Downloads (Pure)


Activation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is emerging as an attractive therapeutic approach to counteract oxidative stress, inflammation, and metabolic imbalances. These processes underpin many chronic pathologies with unmet therapeutic needs, including neurodegenerative disorders and metabolic diseases. As the NRF2 field transitions into the clinical phase of its evolution, the need for an understanding of the factors influencing NRF2 pharmacology has never been greater. In this opinion article we describe the rationale for targeting NRF2, summarise the recent advances in drug development of NRF2 modulators, and reflect on the remaining challenges in realising the full clinical potential of NRF2 as a therapeutic target.

Original languageEnglish
Pages (from-to)137-149
Number of pages13
JournalTrends in Pharmacological Sciences
Issue number3
Early online date9 Jan 2023
Publication statusPublished - Mar 2023


  • NRF2
  • KEAP1
  • electrophile
  • oxidative stress
  • inflammation
  • chronic disease


Dive into the research topics of 'Advances and challenges in therapeutic targeting of NRF2'. Together they form a unique fingerprint.

Cite this